ACOG Stock Overview
A clinical stage biopharmaceutical company, engages in the development of treatments for Alzheimer’s disease and amyotrophic lateral sclerosis (ALS). More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Alpha Cognition Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$8.00 |
| 52 Week High | CA$24.75 |
| 52 Week Low | CA$7.00 |
| Beta | 3.29 |
| 11 Month Change | -40.74% |
| 3 Month Change | -46.67% |
| 1 Year Change | -16.88% |
| 33 Year Change | -70.91% |
| 5 Year Change | n/a |
| Change since IPO | -74.40% |
Recent News & Updates
Recent updates
Shareholder Returns
| ACOG | CA Biotechs | CA Market | |
|---|---|---|---|
| 7D | -0.6% | -8.5% | 0.7% |
| 1Y | -16.9% | 1.5% | 21.7% |
Return vs Industry: ACOG underperformed the Canadian Biotechs industry which returned -0.4% over the past year.
Return vs Market: ACOG underperformed the Canadian Market which returned 21.4% over the past year.
Price Volatility
| ACOG volatility | |
|---|---|
| ACOG Average Weekly Movement | 16.8% |
| Biotechs Industry Average Movement | 11.7% |
| Market Average Movement | 8.3% |
| 10% most volatile stocks in CA Market | 17.6% |
| 10% least volatile stocks in CA Market | 2.9% |
Stable Share Price: ACOG's share price has been volatile over the past 3 months compared to the Canadian market.
Volatility Over Time: ACOG's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of Canadian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | n/a | Michael McFadden | www.alphacognition.com |
Alpha Cognition Inc., a clinical stage biopharmaceutical company, engages in the development of treatments for Alzheimer’s disease and amyotrophic lateral sclerosis (ALS). The company offers ZUNVEYL (benzgalantamine) for the treatment of mild-to-moderate Alzheimer’s disease and mild traumatic brain injury. It also develops ALPHA-0602, a gene therapy for the treatment of ALS; and ALPHA-0702 and ALPHA-0802, a granulin epithelin motifs for the treatment of neurodegenerative diseases.
Alpha Cognition Inc. Fundamentals Summary
| ACOG fundamental statistics | |
|---|---|
| Market cap | CA$124.25m |
| Earnings (TTM) | -CA$20.55m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-6.0x
P/E RatioIs ACOG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ACOG income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$55.00k |
| Gross Profit | -US$55.00k |
| Other Expenses | US$14.64m |
| Earnings | -US$14.70m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.95 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -75.8% |
How did ACOG perform over the long term?
See historical performance and comparison